MSAA’s chief medical officer answers questions sent in by readers.
Read News ArticleAuthor: Hoff Communications
Research News
Information is provided on three investigational medications.
Read News ArticleProgram Notes: MSAA Launches Redesigned Website
MSAA’s redesigned website and new pseudobulbar affect (PBA) video.
Read News ArticleThoughts about Giving: A Fitting Tribute
A tribute gift is a great way to honor or remember someone special.
Read News ArticleStories to Inspire: Challenged Yet Charming
This inspiring author talks about her challenged yet charming life.
Read News ArticleSpread the Word
Three books from MSAA’s free Lending Library are featured.
Read News ArticleMRI Access Program
The MRI Access Fund assists financially challenged individuals requiring a cranial magnetic resonance imaging (MRI) exam for MS diagnosis or disease evaluation.
Read News ArticleIbudilast Receives Fast Track Designation from FDA
MediciNova, Inc., the biopharmaceutical company developing ibudilast (MN-166), announced that this investigational medication for progressive forms of MS has received Fast Track designation from the United States Food and Drug Administration (FDA). This designation is intended for drugs under development for treating serious diseases and with the potential to address unmet medical needs for such diseases.
Read News Article